Davide Rossi and colleagues from Novara in Italy addressed the interesting issue of low-allele frequency p53 mutations and their prognostic impact in CLL (also discussed in AML, see above). This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.